

# Immunosuppressants (for SOT) Treatment Selector

Charts revised July 2019. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/ F/TAF	DTG	EVG/c/ F/TAF	EVG/c/ F/TDF	RAL	ABC	FTC or 3TC	F/TAF	TDF	ZDV
<b>Corticosteroids</b>																					
Prednisone	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓20%	↓	↓	↔	↔	↔	↑11%	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔	↔	↔
<b>Antimetabolites</b>																					
Azathioprine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ <sup>b</sup>
Mycophenolate	↔	↓ <sup>c</sup>	↔	↓ <sup>c</sup>	↓ <sup>c</sup>	↔	↓ <sup>c</sup>	↔	↓13%	↔	↔	↔	↔	↔	↑↑ <sup>d</sup>	↔	↓?	↔	↔	↑↑ <sup>e</sup>	↓?
<b>Calcineurin inhibitors</b>																					
Ciclosporin	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↑	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↑	↑	↑ <sup>g</sup>	↔	↑ <sup>c</sup>	↑ <sup>c</sup>	↔	↔	↔	↑ <sup>h</sup>	↑ <sup>e</sup>	↔
Tacrolimus	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↑ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↔	↔	↔	↔	↑ <sup>c</sup>	↑ <sup>c</sup>	↔	↔	↔	↔	↔ <sup>e</sup>	↔
<b>mTOR inhibitors</b>																					
Everolimus	↑	↑	↑	↑	↑	↔	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sirolimus	↑	↑	↑	↑	↑	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↓ <sup>c</sup>	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔	↔ <sup>e</sup>	↔
<b>Other</b>																					
Anti-thymocyte globulin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ <sup>b</sup>	↔ <sup>b</sup>	↔	↔	↔	↔	↔	↔
Basiliximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Belatacept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

## Colour Legend

	No clinically significant interaction expected.
	These drugs should not be coadministered.
	Potential interaction which may require a dose adjustment or close monitoring.
	Potential interaction predicted to be of weak intensity. No <i>a priori</i> dosage adjustment is recommended.

## Text Legend

↑	Potential increased exposure of the immunosuppressant	↑↑	Potential increased exposure of HIV drug
↓	Potential decreased exposure of the immunosuppressant	↓↓	Potential decreased exposure of HIV drug
↔	No significant effect		

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

## Notes

- a Risk of elevated corticosteroid levels, Cushing's syndrome and adrenal suppression.
- b Potential additive haematotoxicity.
- c TDM of immunosuppressant is recommended.
- d Concentrations of tenofovir-DP may increase, but no effect on elvitegravir, cobicistat or emtricitabine is expected. Monitor renal function.
- = Monitor renal function.
- g Coadministration may increase concentrations of bictegravir and tenofovir alafenamide; no effect on emtricitabine is expected.
- h Coadministration may increase concentrations of tenofovir alafenamide; no effect on emtricitabine is expected.